Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation
Genentech is conducting a first-in-human Phase I/II study of GDC-7035 targeting KRAS G12D mutations in advanced solid tumors.
Asset / Drug
Drug and asset intelligence for GDC-7035 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
KRAS Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.